Biodexa Pharmaceuticals 관리

관리 기준 확인 3/4

Biodexa Pharmaceuticals CEO는 Stephen Stamp, Sep2019 에 임명되었습니다 의 임기는 5.17 년입니다. 총 연간 보상은 £ 252.00K, 99.2% 로 구성됩니다. 99.2% 급여 및 0.8% 보너스(회사 주식 및 옵션 포함). 는 € 4.54 가치에 해당하는 회사 주식의 0% 직접 소유합니다. 4.54. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 7.5 년입니다.

주요 정보

Stephen Stamp

최고 경영자

UK£252.0k

총 보상

CEO 급여 비율	99.2%
CEO 임기	5.2yrs
CEO 소유권	0.0002%
경영진 평균 재임 기간	2.4yrs
이사회 평균 재임 기간	7.5yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Stephen Stamp 의 보수는 Biodexa Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-UK£7m
Mar 31 2024	n/a	n/a	-UK£7m
Dec 31 2023	UK£252k	UK£250k	-UK£7m
Sep 30 2023	n/a	n/a	-UK£8m
Jun 30 2023	n/a	n/a	-UK£8m
Mar 31 2023	n/a	n/a	-UK£8m
Dec 31 2022	UK£238k	UK£236k	-UK£8m
Sep 30 2022	n/a	n/a	-UK£7m
Jun 30 2022	n/a	n/a	-UK£5m
Mar 31 2022	n/a	n/a	-UK£5m
Dec 31 2021	UK£329k	UK£187k	-UK£5m
Sep 30 2021	n/a	n/a	-UK£7m
Jun 30 2021	n/a	n/a	-UK£8m
Mar 31 2021	n/a	n/a	-UK£15m
Dec 31 2020	UK£193k	UK£175k	-UK£22m
Jun 30 2020	n/a	n/a	-UK£22m
Mar 31 2020	n/a	n/a	-UK£16m
Dec 31 2019	UK£207k	UK£50k	-UK£9m

보상 대 시장: Stephen 의 총 보상 ($USD 319.77K ) German 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 473.78K ).

보상과 수익: 회사가 수익성이 없는 동안 Stephen 의 보상이 증가했습니다.

CEO

Stephen Stamp (62 yo)

5.2yrs

테뉴어

UK£252,003

보상

Mr. Stephen A. Stamp serves as Chief Financial Officer and Director of Biodexa Pharmaceuticals Plc (formerly known as Midatech Pharma plc) since September 9, 2019. He serves as Chief Executive Officer at B...

리더십 팀

이름	위치	테뉴어	보상	소유권
Stephen Stamp	CEO, CFO	5.2yrs	UK£252.00k	0.00017% € 4.5
Daniel Palmer	Vice President of Technology	3.8yrs	데이터 없음	데이터 없음
Nicola Tuckwell	VP & Head of Clinical Operations	less than a year	데이터 없음	데이터 없음
Steve Ellul	Chief Business Officer	less than a year	데이터 없음	데이터 없음
Fiona Sharp	Group Financial Controller	no data	데이터 없음	데이터 없음

2.4yrs

평균 재임 기간

경험이 풍부한 관리: 5MP1 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Stephen Stamp	CEO, CFO	5.2yrs	UK£252.00k	0.00017% € 4.5
Simon Turton	Senior Independent Non-Executive Director	9.9yrs	UK£31.92k	0.00017% € 4.5
Stephen Parker	Independent Non-Executive Chairman	2.4yrs	UK£82.00k	데이터 없음
Daniel McCurdy	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Sijmen de Vries	Independent Non-Executive Director	20.1yrs	UK£31.92k	0.00017% € 4.5
Michael Natan	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Francesco Stellaci	Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
David Male	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Lorraine O'Driscoll	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Soledad Penades	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jean-Christophe Roux	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Silke Krol	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

7.5yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: 5MP1 의 이사회는 경험(평균 재직 기간 7.5 년)으로 간주됩니다.

Biodexa Pharmaceuticals 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Biodexa Pharmaceuticals Plc, Annual General Meeting, Jun 13, 2024

Biodexa Appoints Ann Merchant to the Board of Directors

Biodexa Pharmaceuticals Plc, Annual General Meeting, Jun 14, 2023

Midatech Pharma PLC Announces Directorate Change

Midatech Pharma plc Announces Retirement of Rolf Stahel

Midatech Pharma plc, Annual General Meeting, Jun 20, 2022

Recent updates

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadlier Brain Cancer

Biodexa Announces Successful Appeal of Nasdaq Delisting

Biodexa Pharmaceuticals PLC Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

First half 2024 earnings released: UK£0.40 loss per share (vs UK£14.39 loss in 1H 2023)

Biodexa Pharmaceuticals plc Announces to Made the Final Match Payment with Respect to A $17 Million Grant from the Cancer Prevention Research Institute of Texas

Biodexa Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination - Plans to Appeal

Biodexa Pharmaceuticals Plc has completed a Follow-on Equity Offering in the amount of $5.009969 million.

Biodexa Pharmaceuticals Plc has completed a Follow-on Equity Offering in the amount of $5.009968 million.

Biodexa Pharmaceuticals Plc Announces Additional Positive Results of Phase 2 Trial of eRapa in Treatment of Precancerous Polyps in the GI Tract - Now 12-Month Data

Biodexa Pharmaceuticals PLC Announces Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024

Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ At 12 Months in Familial Adenomatous Polyposis (Fap)

Biodexa Pharmaceuticals plc Announces Promising Phase 2 Results for Its Newly In-Liced Drug Erapa for Treating Fam Fam Famic Adenomatous Polyposis

Biodexa Pharmaceuticals PLC Announces Positive Statistically Significant Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting

Biodexa Pharmaceuticals Plc, Annual General Meeting, Jun 13, 2024

Full year 2023 earnings released: UK£8.00 loss per share (vs UK£620 loss in FY 2022)

New minor risk - Financial data availability

Biodexa Pharmaceuticals Plc's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

Biodexa Pharmaceuticals plc Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

New major risk - Financial position

Biodexa Pharmaceuticals plc Reports 12 Month Survival in Magic-G1 Study of Mtx110 in Recurrent Glioblastoma Patients

Biodexa Appoints Ann Merchant to the Board of Directors

Biodexa Pharmaceuticals Plc has completed a Composite Units Offering in the amount of $5.217389 million.

New major risk - Financial position

Biodexa Pharmaceuticals plc Completes Recruitment of Cohort A in Study of Mtx110 in Patients with Recurrent Glioblastoma

Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of Mtx-110 (Magic-G1 Study) in Patients with Recurrent Glioblastoma At 2023 Annual European Association of Neuro-Oncology Meeting (Eano)

Biodexa Regain Compliance with Nasdaq Minimum Bid Price Requirement

Biodexa Ltd Announces Completion of Enrolment and Treatment in the Phase 1 Study of Mtx110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (Dmgs)

Biodexa Pharmaceuticals Announces Results of Appeal of Delisting Determination

Biodexa Pharmaceuticals plc Announces the Publication of the Results of an Investigator-Initiated Phase I Study Pnoc015

Biodexa Pharmaceuticals Receives a Period of 180 Calendar Days to Return to Compliance with the Minimum Bid Price Rule

Biodexa Pharmaceuticals Receives Staff Determination Letter from Nasdaq to Delist its Securities from The Nasdaq Capital Market Regarding Non-Compliance with the Minimum Bid Price Requirements

Biodexa Pharmaceuticals Plc announced that it has received $3.320388 million in funding

Biodexa Pharmaceuticals Plc, Annual General Meeting, Jun 14, 2023

Biodexa Pharmaceuticals Plc (NasdaqCM:BDRX) entered into non-binding letter of intent to acquire Varian Biopharmaceuticals Inc. for $3.7 million.

Full year 2022 earnings released: UK£0.077 loss per share (vs UK£1.36 loss in FY 2021)

Midatech Pharma plc announced that it has received $5.999223 million in funding

Midatech Pharma Announces Receipt of NASDAQ Notice

Midatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 Study

Midatech Pharma plc (AIM:MTPH) entered into a definitive agreement to acquire Bioasis Technologies Inc. (TSXV:BTI) from The Lind Partners, LLC and others for $5.5 million.

Midatech Pharma plc announced that it expects to receive $10 million in funding

Midatech Pharma plc Announces First Patient Enrolled in Phase 1 Study of MTX-110

Midatech Pharma plc Announces Receipt of Nasdaq Notification

Midatech Pharma PLC Announces Directorate Change

Midatech Pharma plc Announces MTX110 Study to be Presented at ISPNO 2022

Midatech Pharma plc Announces Retirement of Rolf Stahel

Midatech Pharma plc Announces Fast Track Designation Granted to Mtx110 Development for the Treatment of Recurrent Glioblastoma

Midatech Pharma plc, Annual General Meeting, Jun 20, 2022

Midatech Pharma Received Written Notification from Nasdaq Stating Company Is Not in Compliance with Minimum Bid Price Requirement

Midatech Pharma PLC Announces Investigational New Drug Application for Study of MTX110 in Recurrent Glioblastoma (GBM) Becomes Effective

Midatech Pharma plc has completed a Follow-on Equity Offering in the amount of £10 million.

Midatech Pharma plc Announces Shut Down of its Bilbao Operations

Midatech Pharma PLC to Present MTX110 Programmes at The International Symposium on Pediatric Neuro-Oncology, Karuizawa, Japan

Midatech Pharma plc Announces Headline Results of MTX110 Phase I DIPG Study

Midatech Pharma plc to Report First Half, 2020 Results on Sep 10, 2020

Midatech Pharma plc has completed a Follow-on Equity Offering in the amount of £5 million.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령